Medicus Pharma to Present at BIO-Europe 2026
The company says its chief medical officer will highlight its precision oncology focus, including its CD228V-targeted ADC and partner-ready therapeutic programs.
The company says its chief medical officer will highlight its precision oncology focus, including its CD228V-targeted ADC and partner-ready therapeutic programs.